Open-label Study With Bosentan in Interstitial Lung Disease

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion
• Treatments: Bosentan

Criteria

Inclusion Criteria:

• To have completed the 12-month treatment period of the AC-052-330/BUILD 2.

• Women should not be pregnant

• Women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception

• Signed informed consent prior to initiation of any study-mandated procedure

Exclusion Criteria:

• Any major violation of the protocol AC-052-330.